Neuroleptic malignant syndrome in the Emergency Department
Emergencias Pediátricas · 26.06.2026 · 5 (2) · 23-29
DOI: 10.65350/emped.v5n2.en.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Emergencias Pediátricas, online erschienen am 26.06.2026. Verfasst von Carlos-Javier Moreno-Pérez und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Neuroleptic malignant syndrome (NMS) is a severe, rare adverse reaction associated with the use of neuroleptics. Its pathophysiology is related to central dopaminergic blockade, affecting thermoregulation, muscle tone, and the autonomic nervous system.Epidemiology: More prevalent in adults, pediatric cases have been reported, especially in males treated with typical or atypical antipsychotics. Its incidence is low but might be underestimated.Risk factors: These include pharmacological aspects (high doses, rapid titration, polypharmacy), intrinsic patient factors (neurological comorbidities, family history), and environmental factors (dehydration, immobilization, infections).Clinical presentation: Fever, rigidity, altered mental status, and autonomic instability may appear. It can progress to rhabdomyolysis, renal failure, and metabolic disturbances.Diagnosis: It is clinical, based on criteria such as those of Levenson, Lazarus, and the DSM-5. It requires the exclusion of other entities like serotonin syndrome, malignant catatonia, or meningitis.Treatment: It requires discontinuation of the neuroleptic, intensive support (hydration, temperature control, ventilation, electrolyte correction), and specific treatment with dantrolene and bromocriptine. Benzodiazepines can be useful as adjuvant therapy.Neuroleptic reintroduction: It must be done with caution, using low doses and avoiding the parenteral route.
Conclusion
NMS demands early diagnosis and multidisciplinary management. In pediatrics, its presentation may be atypical, so it should be considered following any change in neuroleptic treatment.
Zitieren
APA
Moreno-Pérez, C., Pieras-López, Á., & Duero-Adrados, M. (2026). Neuroleptic malignant syndrome in the Emergency Department. Emergencias Pediátricas, 5(2), 23-29. https://doi.org/10.65350/emped.v5n2.en.005
Vancouver
Moreno-Pérez C, Pieras-López Á, Duero-Adrados M. Neuroleptic malignant syndrome in the Emergency Department. Emergencias Pediátricas. 2026;5(2):23-29. doi:10.65350/emped.v5n2.en.005
BibTeX
@article{MorenoPrez2026,
author = {Moreno-Pérez, Carlos-Javier and Pieras-López, Ángela and Duero-Adrados, Marta},
title = {Neuroleptic malignant syndrome in the Emergency Department},
journal = {Emergencias Pediátricas},
year = {2026},
volume = {5},
number = {2},
pages = {23--29},
doi = {10.65350/emped.v5n2.en.005}
}
EUVIMED